Table of contents:
Paxlovid is a new antiviral drug candidate being researched for its potential for the treatment of COVID-19. So far, studies have shown that Paxlovid is quite effective in reducing the risk of death and hospitalization of COVID-19 patients
Paxlovid is a trademark of the combination antiviral PF-07321332 and ritonavir developed by Pfizer as a cure for COVID-19.
This antiviral drug has gone through final clinical trials and is currently applying for an emergency use permit to the United States Food and Drug Administration (FDA), because of its extraordinary effectiveness against the SARS-CoV-2 virus which is also often called the virus. Corona.
How Paxlovid Works for COVID-19
The use of the antiviral drug Paxlovid is taken by mouth. This drug is given to COVID-19 patients with the aim of preventing the severity of the disease, hospitalization, and death.
Paxlovid contains a new antivirus, namely PF-07321332, which works by blocking the activity of the SARS-CoV-2-3CL protease or the enzyme that causes the Corona virus to replicate. This new antivirus will inhibit virus replication at the proteolysis stage that occurs before viral RNA replication.
The use of this antiviral drug is combined with low-dose ritonavir, which aims to slow down the metabolism of PF-07321332 in the body. A slow metabolism will keep the antivirus active in the long term, making it effective against the Corona virus in the body.
Ritonavir belongs to a group of protease inhibitor drugs that are used to help other medicines work properly in the body. Ritonavir is usually combined with lopinavir (lopinavir-ritonavir) to inhibit disease progression in HIV-infected patients.
In the final stage of clinical trials, Paxlovid demonstrated its effectiveness against the Corona virus. This makes it the second oral antiviral that could potentially be used in the treatment of COVID-19. Previously, molnupiravir had shown good results in controlling the number of Corona viruses.
Paxlovid Clinical Trial Results for COVID-19
To ensure the safety and effectiveness of medicines, it is necessary to conduct clinical trials first before being distributed to the general public. There are four phases of clinical trials that must be passed before a drug is finally approved by the appropriate safety authorities.
Paxlovid which is a combination of ratinovir and PF-07321332 must also go through predetermined clinical trials, so that later it can be used widely.
During clinical trials, Paxlovid was administered orally every 12 hours for 5 days to people with COVID-19 with mild to moderate symptoms and who had at least one medical condition that could exacerbate the disease. Paxlovid antiviral drug is given since the onset of symptoms.
The results of phase II/III clinical trials showed that Paxlovid was able to reduce the risk of hospitalization or death by up to 89%. Until the 28th day of the clinical trial, there were no reported cases of death from COVID-19 patients receiving Paxlovid.
Due to its extremely high effectiveness, Pfizer as the main laboratory that developed Paxlovid is currently seeking to apply for an Emergency Use Authorization (Emergency Use Authorization) to the FDA.
The effectiveness of Paxlovid as an antiviral drug for COVID-19 in this clinical trial is certainly a breath of fresh air for the handling of the global pandemic.
Although the development of Paxlovid is very promising and community activities have begun to be relaxed, COVID-19 prevention measures should not be ignored.
Always obey the he alth protocol by washing your hands with soap or hand sanitizer, wearing a mask when doing activities outside the home, keeping your distance, avoiding crowds, and don't complete the COVID-19 vaccine dose when you have a schedule.
If you still have questions about Paxlovid and other COVID-19 treatments, consult your doctor directly to get the right answer. For an easier consultation, you can chat with the doctor through the ALODOKTER application.